Max Planck, Alnylam Sue Whitehead, MIT, UMass for Breach of Contract in RNAi Patent Filings | GenomeWeb

This article was originally published on June 29.

The Max Planck Society, Max Plank Innovation, and Alnylam Pharmaceuticals are suing a trio of Massachusetts research institutions for allegedly breaching their contractual and fiduciary duties in prosecuting patents surrounding RNA interference technology.

The complaint, filed late last week in Suffolk County Superior Court in Boston, names as defendants the Whitehead Institute for Biomedical Research, the Massachusetts Institute of Technology, and the University of Massachusetts.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.